Introduction

25
The increasing availability of antiretroviral therapy (ART) for 26 HIV-infected individuals has led to a dramatic reduction in AIDS-27 related mortality and to the emergence of liver-related complica-28 tions of hepatitis B virus (HBV) and hepatitis C virus (HCV) 29 infections as a major cause of death. 1 Western Europe, where the majority of patients are infected as 48 adults. 6 As HBV transmission patterns and the duration of infection 49 may influence the development of liver fibrosis and HCC, HIV/HBV 50 co-infected patients in SSA could be at high risk of developing early 51 liver disease. 5 In addition, the burden of HBV-related complica-52 tions might be increased by the presence of concurrent infections 53 such as hepatitis delta virus (HDV) and schistosomal infections, as 54 well as environmental exposures such as aflatoxins. 20 
117
In the SHCS, alcohol intake has been assessed routinely at 118 6-month intervals since 2005. 21 In Zambia, alcohol consumption 119 was investigated in all patients at ART initiation using the AUDIT-C 120 tool. 22 At-risk alcohol intake was defined according to the National Table 2 ). The 201 estimates were similar when each cohort was analyzed separately Table S1 ). Of 235 note, there was no clear difference in the proportion of patients 236 with significant liver fibrosis between HIV/HBV co-infected 237 patients with moderate and those with high viral loads in Zambia 238 (Figure 3 ). Among patients with high HBV viral loads, 72% in 239 Zambia and 58% in Switzerland had normal aminotransferases and 240 only one of these 47 patients had significant fibrosis. After 241 exclusion of these potentially immune-tolerant patients, the Figure 2 . Risk factors for significant liver fibrosis (APRI !1.5) from multivariable logistic regression, by cohort.
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proportion of individuals with significant fibrosis among those 243
with high viral loads increased from 13% to 36% in Zambia and from 244 21% to 50% in Switzerland.
245
Discussion
246
In this cross-sectional study of HIV-infected, ART-naïve adults 247 in Zambia and Switzerland, it was found that HBV co-infection was 248 strongly associated with liver fibrosis. HIV/HBV co-infected 249 patients were at least three times more likely to have significant 250 fibrosis compared to HIV monoinfected individuals. This associa-251 tion was similar in Zambia and Switzerland despite differences in 252 the natural history of HBV infection and the genetic background of 253 the study populations, and seemed to be driven by HBV viral load. 254 Liver cirrhosis was rare in Zambia but present in over 10% of HIV/ 255 HBV co-infected individuals in Switzerland. This analysis also 256 showed differences in alcohol intake and the impact on liver 257 disease between the two regions, underlining the need to better 258 characterize alcohol consumption and its health-related effects in 259 Sub-Saharan Africa. 260
Few studies have evaluated the impact of HBV co-infection on 261 the development of liver fibrosis in HIV-infected individuals using 262 non-invasive methods. The Multicenter AIDS Cohort Study (MACS)  263 showed a strong association between viral hepatitis co-infection 264 and significant liver fibrosis using the APRI score, but the number 265 of HBV-infected patients analyzed was small. 19 In SSA, two studies Stockdale et al. showed that the APRI score had a good negative 278 predictive value for excluding cirrhosis and significant fibrosis 279 among HIV/HBV co-infected individuals in West Africa, but had a 280 poor overall diagnostic performance. 24 As APRI is now recom-281 mended by the WHO to evaluate treatment eligibility for chronic 282 HBV infection in the absence of liver biopsy or transient 283 elastography, 13, 14, 25 there is an urgent need for validation studies 284 of this marker in other contexts, ideally in comparison with the 285 results of liver biopsies.
286 The association between HBV infection and liver fibrosis was 287 found to depend on the level of HBV viral replication. In both 288 countries, the proportion of patients with significant liver fibrosis 289 was similar in HBV-uninfected and HBV co-infected patients with a 290 viral load <20 IU/ml, whereas the prevalence of liver disease was 291 much higher in those with high viral loads. These results are in line 292 with those of prospective studies on viral replication in HBV 293 monoinfected individuals and the risk of liver cirrhosis and 294 HCC. 26, 27 HBV replication is influenced by the natural history of 295 HBV infection: patients infected during early childhood are likely 296 to undergo hepatitis B e antigen (HBeAg) seroconversion early in 297 life and to remain in a non-replicating phase for many years, 298 whereas those acquiring chronic HBV infection in adulthood often 299 experience high-level replication, hepatic inflammation, and 300 progressive development of liver fibrosis. 5 317 Another important difference between patients in Zambia and 318 Switzerland was the difference in the association between alcohol 319 consumption and liver disease. At-risk alcohol consumption did 320 not seem to be a strong risk factor for hepatic damage in Zambia, 321 whereas there was a clear association with significant liver fibrosis 322 in Switzerland. Due to the paucity of data published on alcohol 323 consumption and related health consequences in HIV-infected 324 individuals in SSA, it was difficult to evaluate the generalizability 325 and robustness of these data. However, besides the potential 326 explanations mentioned above, the nature of the alcohol assess-327 ment could have influenced the results. Self-reported alcohol 328 intake is subject to several biases and socio-cultural differences 329 between the two settings studied, making the comparison difficult. 330 More research on alcohol-related and metabolic-induced liver 331 complications is urgently needed to improve our understanding of 332 liver disease progression in SSA, especially in HIV-infected 333 populations, in which alcohol consumption is high. 334 This assessment of liver-related complications using detailed 335 assessments of HBV virological determinants as well as other risk 336 factors for liver disease, including alcohol consumption and HIV 337 stage of disease, is a unique strength of this study. The impact of 338 HCV co-infection on liver fibrosis could be excluded, as all patients 339 were tested for HCV infection, including in the Zambian cohort. The 340 association between HBV replication and liver fibrosis could 341 be tested, as viral load measurements were available for >80% of 342 the HBV co-infected participants. However, due to missing HBeAg 343 data in a large sample of the patients, the influence of HBeAg 344 positivity could not be evaluated. As the majority of adult patients 345 with HBV infection in SSA are HBeAg-negative, these data could 346 have explained the differences in the prevalence of liver cirrhosis 347 between the two settings. Similarly, data on hepatitis delta 348 infection, a well-known risk factor for liver fibrosis in HIV/HBV co-349 infected individuals, were not available. Another limitation of 350 this study was the reliance on the APRI score to measure liver 351 fibrosis and cirrhosis. As this test has not been properly validated in 
